Bacterial conjunctivitis
Drug research and approvals for bacterial conjunctivitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 5 studies of bacterial conjunctivitis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 1 drug trials for it since 2013.
- Recruiting worldwide: 5
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 0
- Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the EyeNCT07634913 · Not reported · Zhongshan Ophthalmic Center, Sun Yat-sen University · starts Dec 12, 2023
- Safety and Efficacy of SUM-191 for Patients With Bacterial ConjunctivitisNCT07565103 · Phase 1 / Phase 2 · Senju USA, Inc. · starts Jun 25, 2026
- RESTORE: Comparing Two Approaches to Repeat TT Surgery Performed by Integrated Eye Care Workers (IECWs)NCT07322302 · Not applicable · University of North Carolina, Chapel Hill · starts Jan 13, 2026
- Efficacy of Fusidic Acid 1% in the Treatment of Bacterial ConjunctivitisNCT06911424 · Phase 3 · Baxis Pharmaceuticals, Inc. · starts Mar 21, 2025
- Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular SurfaceNCT04198740 · Not reported · Centre hospitalier de l'Université de Montréal (CHUM) · starts Feb 1, 2020
Approved 5
- MoxifloxacinTopoisomerase IV inhibitor
- GatifloxacinDNA gyrase inhibitor
- BesifloxacinTopoisomerase IV inhibitor
- AzithromycinBacterial 70S ribosome inhibitor
- LevofloxacinDNA gyrase inhibitor
Phase 3 4
- Tobramycin70S ribosome inhibitor
- OfloxacinBacterial DNA gyrase inhibitor
- VancomycinPeptidoglycan inhibitor
- PazufloxacinBacterial DNA gyrase inhibitor
Phase 2 1
How its trials ended
38 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 16 whose ending is known, 63% met their primary endpoint, 0% missed it and 38% stopped early.
- Completed, result not reported1847%
- Met its primary endpoint1026%
- Stopped: other or unclear38%
- Status unknown38%
- Stopped: sponsor or business decision25%
- Ongoing13%
- Stopped: enrollment or feasibility13%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Jul 6, 2017 | A phase 3, multi-center, randomized, double-masked study to evaluate the clinical efficacy and safety of SHP640 (pvp-iodine 0.6% and dexamethasone 0.1%)…SHP640 (FST-100) | Takeda Pharmaceuticals USA | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA